Skip to main content
. 2020 Sep 20;25(18):4310. doi: 10.3390/molecules25184310

Figure 3.

Figure 3

Effects of imatinib and sorafenib on the expression of TGFB1, TGFB2, PDGF, and IL6. Mice were challenged with Concanavalin A for four weeks and then treated with either imatinib, sorafenib, a combination of imatinib and sorafenib, or vehicle for three weeks. At the end of the treatment period, mice were euthanized and their livers were collected for the determination of TGFB1 (A), TGFB2 (B), PDGF (C), and IL6 (D) via real-time PCR. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.